Carboxyhemoglobin concentration as an index of bilirubin production in neonates with birth weights less than 1,500 grams: a randomized double-blind comparison of supplemental oral vitamin E and placebo.
A randomized double-blind study of the efficacy of oral vitamin E supplementation as a prophylactic treatment for hyperbilirubinemia was undertaken in preterm infants weighing less than 1,500 g. Hemoglobin (Hb) levels, blood carboxyhemoglobin saturation (HbCOc), end-tidal carbon monoxide concentration (ETCO), and serum total bilirubin levels were determined in each subject on the first and third days of the study. We found no differences between the vitamin E-treated and placebo-treated groups with respect to Hb, HbCOc, ETCO, or serum bilirubin levels on day 1 or 3. In addition, we reanalyzed our data to compare those infants who had low vitamin E levels at birth with those who had vitamin E levels greater than 0.4 mg/dl on day 1. We still observed no differences in Hb, HbCOc, ETCO, or serum bilirubin levels on day 1 or 3. The results of our study suggest that supplemental oral vitamin E therapy has no major effect on bilirubin production during the first 3 days of life in premature infants weighing less than 1,500 g at birth.
Fischer
A F
AF
Stanford University School of Medicine, Department of Pediatrics, CA 94305.
Inguillo
D
D
Martin
D M
DM
Ochikubo
C G
CG
Vreman
H J
HJ
Stevenson
D K
DK
D000284:Administration, Oral; D001663:Bilirubin / Q000096:biosynthesis*; D002263:Carboxyhemoglobin / Q000032:analysis*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007230:Infant, Low Birth Weight / Q000378:metabolism*; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000517:prevention & control*; D010919:Placebos; D011897:Random Allocation; D014810:Vitamin E / Q000008:administration & dosage / Q000627:therapeutic use*
D010919:Placebos; D014810:Vitamin E; D002263:Carboxyhemoglobin; D001663:Bilirubin